These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 32810638

  • 1. In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood.
    Papalini C, Sabbatini S, Monari C, Mencacci A, Francisci D, Perito S, Pasticci MB.
    J Glob Antimicrob Resist; 2020 Dec; 23():4-8. PubMed ID: 32810638
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.
    Wang F, Zhou Q, Yang X, Bai Y, Cui J.
    PLoS One; 2021 Dec; 16(10):e0258426. PubMed ID: 34648556
    [Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae.
    Zhang W, Guo Y, Li J, Zhang Y, Yang Y, Dong D, Zhu D, He P, Hu F.
    Antimicrob Resist Infect Control; 2018 Dec; 7():142. PubMed ID: 30479755
    [Abstract] [Full Text] [Related]

  • 4. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella pneumoniae.
    Ojdana D, Gutowska A, Sacha P, Majewski P, Wieczorek P, Tryniszewska E.
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [Abstract] [Full Text] [Related]

  • 5. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
    Zheng M, Li FH, Liu J, Li WJ, Yin RX, Cai DT, Andrey DO, Zheng SL, Gales AC, Zhang WJ, Sun J, Liao XP, Yu Y.
    J Antimicrob Chemother; 2024 May 02; 79(5):1069-1080. PubMed ID: 38526879
    [Abstract] [Full Text] [Related]

  • 6. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P, Re MC, Campoli C, Viale PL, Ambretti S.
    Clin Microbiol Infect; 2020 Apr 02; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [Abstract] [Full Text] [Related]

  • 7. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I, Antoniadou A, Karaiskos I, Kontopoulou K, Giamarellou H, Souli M.
    Clin Microbiol Infect; 2019 Jun 02; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [Abstract] [Full Text] [Related]

  • 8. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, Solomou A, Tsiata E, Anastassiou ED, Fligou F, Marangos M, Spiliopoulou I, Christofidou M.
    J Antimicrob Chemother; 2019 Jul 01; 74(7):2051-2054. PubMed ID: 31002313
    [Abstract] [Full Text] [Related]

  • 9. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae.
    Wu Y, Yu W, Chu X, Zhang J, Jia P, Liu X, Zhu Y, Xu Y, Yang Q.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0010724. PubMed ID: 38712934
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
    Bianco G, Boattini M, Comini S, Iannaccone M, Bondi A, Cavallo R, Costa C.
    Eur J Clin Microbiol Infect Dis; 2022 Jan 04; 41(1):63-70. PubMed ID: 34462816
    [Abstract] [Full Text] [Related]

  • 11. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
    Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, Viale P, Re MC, Ambretti S.
    Int J Infect Dis; 2017 Dec 04; 65():1-3. PubMed ID: 28951106
    [Abstract] [Full Text] [Related]

  • 12. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, Pongolini S, Berlingeri A, Cristini F, Bartoletti M, Tedeschi S, Ambretti S.
    J Antimicrob Chemother; 2018 Jun 01; 73(6):1525-1529. PubMed ID: 29566151
    [Abstract] [Full Text] [Related]

  • 13. The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.
    Zhang P, Hu H, Shi Q, Sun L, Wu X, Hua X, McNally A, Jiang Y, Yu Y, Du X.
    Antimicrob Agents Chemother; 2023 Mar 16; 67(3):e0127922. PubMed ID: 36794957
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.
    Antinori E, Unali I, Bertoncelli A, Mazzariol A.
    Clin Microbiol Infect; 2020 Jul 16; 26(7):946.e1-946.e3. PubMed ID: 32061796
    [Abstract] [Full Text] [Related]

  • 16. In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae.
    Romanelli F, De Robertis A, Carone G, Dalfino L, Stufano M, Del Prete R, Mosca A.
    New Microbiol; 2020 Jul 16; 43(3):136-138. PubMed ID: 32596740
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
    Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, Kreiswirth BN, Nguyen MH.
    Antimicrob Agents Chemother; 2015 Sep 16; 59(9):5793-7. PubMed ID: 26169413
    [Abstract] [Full Text] [Related]

  • 19. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
    Gaibani P, Bovo F, Bussini L, Lazzarotto T, Amadesi S, Bartoletti M, Viale P, Ambretti S.
    J Antimicrob Chemother; 2022 May 29; 77(6):1570-1577. PubMed ID: 35373297
    [Abstract] [Full Text] [Related]

  • 20. Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study.
    Karaiskos I, Daikos GL, Gkoufa A, Adamis G, Stefos A, Symbardi S, Chrysos G, Filiou E, Basoulis D, Mouloudi E, Galani L, Akinosoglou K, Arvaniti K, Masgala A, Petraki M, Papadimitriou E, Galani I, Poulakou G, Routsi C, Giamarellou H, Hellenic Ceftazidime/Avibactam Registry Study Group.
    J Antimicrob Chemother; 2021 Feb 11; 76(3):775-783. PubMed ID: 33249436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.